Vivanza Biosciences Limited (VIVANZA.BO)
INR 3.5
(-3.58%)
INR 3.5
(-3.58%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 20.43 Million | -2 Million | -5.35 Million | -32.32 Million | 25.42 Million | 4.42 Million |
| Net Income | 5.47 Million | 5.98 Million | 3.33 Million | 753.35 Thousand | -2.05 Million | -4.4 Million |
| Depreciation & Amortization | 121 Thousand | 26 Thousand | 74 Thousand | 98.42 Thousand | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 23.87 Million | -8.01 Million | -8.75 Million | -33.16 Million | 27.48 Million | 8.83 Million |
| Other non-cash items | -9.02 Million | 6.26 Million | 17.58 Million | 36.95 Million | -26.57 Million | -4.99 Million |
| Investing Cash Flow | -375 Thousand | - | - | -211.19 Thousand | - | - |
| Investments in PPE | -375 Thousand | - | - | -211.19 Thousand | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -19.8 Million | 2.86 Million | 5.25 Million | 29.37 Million | -23.19 Million | -4.76 Million |
| Debt repayment | -40.76 Million | -24.88 Million | -19.92 Million | -1.82 Million | -10.94 Million | -1.36 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 20.96 Million | -22.02 Million | -14.67 Million | 27.55 Million | -12.25 Million | -6.12 Million |
| Accounts receivables | 9.4 Million | -46.39 Million | -15.89 Million | 2.88 Million | -8.42 Million | -6.22 Million |
| Accounts payables | -13.14 Million | 40.64 Million | 16.2 Million | -42.78 Million | 24.63 Million | 8.43 Million |
| Inventory | 4.68 Million | -465 Thousand | -17.74 Million | 3.13 Million | 10.37 Million | 2.78 Million |
| Other working capital | 9.78 Million | -1.8 Million | 8.69 Million | 3.59 Million | 907.68 Thousand | 3.83 Million |
| Cash at beginning of period | 1.4 Million | 551 Thousand | -30.92 Million | -27.77 Million | -30 Million | -29.65 Million |
| Cash at end of period | 1.66 Million | 1.4 Million | 551 Thousand | -30.92 Million | -27.77 Million | -30 Million |
| Capital Expenditure | -375 Thousand | - | - | -211.19 Thousand | - | - |
| Effect of forex changes on cash | - | - | - | -1.00 | - | - |
| Net cash flow / Change in cash | 260 Thousand | 858 Thousand | 31.47 Million | -3.15 Million | 2.23 Million | -342.42 Thousand |
| Free Cash Flow | 20.06 Million | -2 Million | -5.35 Million | -32.53 Million | 25.42 Million | 4.42 Million |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 2.65 Million | -4.13 Million | 5.47 Million | 2.06 Million | 2.61 Million | 4.94 Million |
| Depreciation & Amortization | - | - | 121 Thousand | 7000.00 | 7000.00 | 7000.00 |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | -1.76 Million | - | - | - |
| Other non-cash items | -2.65 Million | 4.13 Million | -708 Thousand | -2.06 Million | -2.61 Million | -4.94 Million |
| Investing Cash Flow | - | - | -375 Thousand | - | - | - |
| Investments in PPE | - | - | -375 Thousand | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | -3.18 Million | - | - | - |
| Debt repayment | - | - | -28.27 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | 25.09 Million | - | - | - |
| Accounts receivables | - | - | 9.4 Million | - | - | - |
| Accounts payables | - | - | -13.14 Million | - | - | - |
| Inventory | - | - | 4.68 Million | - | - | - |
| Other working capital | - | - | -2.7 Million | - | - | - |
| Cash at beginning of period | - | - | 1.4 Million | 1.8 Million | -805 Thousand | 1.4 Million |
| Cash at end of period | - | - | 1.66 Million | 2.06 Million | 1.8 Million | 4.94 Million |
| Capital Expenditure | - | - | -375 Thousand | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | 260 Thousand | 253 Thousand | 2.61 Million | 3.53 Million |
| Free Cash Flow | - | - | 3.44 Million | 2.06 Million | 2.61 Million | 4.94 Million |
1879
BDRAF
ORIBEVER
ELECF
AANANDALAK
SARMF